TP53 and familial pancreatic carcinoma: Importantly, similar to PI3K inhibition, CCB treatment of p53 mutant breast and pancreatic cancer cells (MDA-MB-231, P53R280K; PDAC, P53R172H; Su.86.86, P53G245S) significantly impaired cancer cell invasion (Fig. 2a–c), in a concentration-dependent manner (Supplementary Fig. 5A,B).